Vasopressin Dosage Recommendations
For adult vasodilatory shock, initiate vasopressin at 0.03 units/minute as an adjunct to norepinephrine; for cardiac arrest, a single 40 IU dose may be considered; for central diabetes insipidus in adults, continuous infusion starting at 0.5 mU/kg/hour; and for pediatric vasodilatory shock, 0.0002-0.002 units/kg/minute.
Adult Vasodilatory Shock (Septic/Post-Cardiotomy)
The Surviving Sepsis Campaign guidelines strongly recommend vasopressin at 0.03 units/minute (up to 0.04 units/minute maximum) as a second-line agent added to norepinephrine 1. The FDA label confirms dosing of 0.03-0.1 units/minute for post-cardiotomy shock and 0.01-0.07 units/minute for septic shock 2.
Key implementation points:
- Add vasopressin when norepinephrine alone fails to achieve MAP ≥65 mmHg 1, 3
- Do NOT use vasopressin as monotherapy for initial vasopressor support 1
- Doses above 0.03-0.04 units/minute should be reserved for salvage therapy only 1, 3, 1
- The pressor effect peaks within 15 minutes and fades within 20 minutes after stopping 2
Evidence strength: Research demonstrates that 0.067 units/minute may be more effective than 0.033 units/minute in advanced vasodilatory shock requiring norepinephrine >0.6 mcg/kg/min, with comparable adverse event rates 4. However, guidelines conservatively cap recommendations at 0.03-0.04 units/minute for routine use.
Critical caveat: Vasopressin can worsen cardiac function and should not be used without cardiac output/ScvO2 monitoring in cardiogenic shock 5. Ensure adequate fluid resuscitation before initiating any vasopressor 1.
Cardiac Arrest
For adult cardiac arrest, vasopressin 40 IU IV may be administered as a single dose, though evidence does not show superiority over standard epinephrine 6. The 2024 AHA guidelines found no difference in outcomes between vasopressin alone or combined with epinephrine versus epinephrine alone 6.
Emerging evidence: One trial showed vasopressin 20 IU plus methylprednisolone 40 mg after the first epinephrine dose increased ROSC by 9.6% in in-hospital cardiac arrest, though survival and neurological outcomes were not significantly different 6.
Practical approach: If using vasopressin in cardiac arrest, consider alternating 1 mg epinephrine with 40 IU vasopressin every 3-5 minutes during CPR 7. However, standard epinephrine 1 mg every 3-5 minutes remains the primary recommendation 6.
Central Diabetes Insipidus (Adults)
For neurogenic diabetes insipidus, start continuous IV vasopressin at 0.5 mU/kg/hour (approximately 1.3-2.7 mU/kg/hour based on clinical response) 8.
Titration strategy:
- Target urine output <2 mL/kg/hour with increased specific gravity
- Adjust infusion rate to maintain urine output around 65 mL/100 kcal metabolized/day
- Effect typically noted within 1-6 hours
- Hypernatremia correction occurs within 17-53 hours 8
Advantage: Continuous infusion allows rapid onset/termination and easy titration compared to intermittent dosing 8.
Pediatric Patients
Vasodilatory Shock (Post-Cardiac Surgery)
For pediatric vasodilatory shock, use 0.0002-0.002 units/kg/minute 9. This dosing demonstrated significant hemodynamic improvement with increased systemic vascular resistance (from 894±191 to 1138±161 dyn/s/cm/m²), decreased catecholamine requirements, and improved urine output without significant adverse effects 9.
Important distinction: The 2009 pediatric septic shock guidelines note that low-dose vasopressin (≤0.04 units/kg/minute) has short-term hemodynamic benefits in adults, but safety and efficacy in children with septic shock remain unproven pending ongoing trials 5. Use with extreme caution and only when catecholamine-refractory.
Cardiac Arrest (Pediatric)
Vasopressin is NOT routinely recommended for pediatric cardiac arrest 10. The 2025 AHA/AAP guidelines do not include vasopressin in standard pediatric ACLS algorithms. Recent research comparing vasopressin to epinephrine during pediatric in-hospital cardiac arrest showed no significant difference in time to ROSC (aHR 0.73,95% CI: 0.31-1.7) 11.
Standard pediatric cardiac arrest dosing remains:
- Epinephrine 0.01 mg/kg IV/IO (0.1 mL/kg of 1:10,000) every 3-5 minutes
- Maximum single dose 1 mg IV/IO 12, 10
Central Diabetes Insipidus (Neonates/Infants)
Management in neonates/infants is particularly challenging due to inability to communicate thirst, limited renal concentrating capacity, and lack of FDA-approved formulations 13. No specific IV vasopressin dosing is established for neonatal diabetes insipidus; desmopressin alternatives (buccal, oral, subcutaneous) or thiazide diuretics are typically preferred 13.
Critical Safety Considerations
Absolute contraindications:
- Known allergy to vasopressin or chlorobutanol 2
Major warnings:
- Can worsen cardiac function—avoid in cardiogenic shock without hemodynamic monitoring 5, 2
- Risk of ischemic complications (coronary, mesenteric, digital) 2
- May cause reversible diabetes insipidus 2
- Hyponatremia risk, especially with concurrent hydrocortisone (increases vasopressin levels) 4
- Thrombocytopenia 14
Drug interactions:
- Indomethacin doubles the duration of vasopressor effects 2
- Ganglionic blockers increase pressor effect by 20% 2
- Catecholamines have additive pressor effects 2
Preparation and Administration
Dilution (from 20 units/mL vial):
- Dilute with normal saline or D5W to 0.1 units/mL or 1 unit/mL 2
- Discard unused diluted solution after 18 hours at room temperature or 24 hours refrigerated 2
Monitoring requirements: